Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Public Health and Preventive Medicine
  4. Vol 3, Issue 3, 2023

Study on the Influence of National Centralized Drug Procurement on Drug Use in Hospitals in Border Areas—Take Bayingolin Mongolian Autonomous Region of Xinjiang Autonomous Region as an Example

Download as PDF

DOI: 10.23977/phpm.2023.030302 | Downloads: 12 | Views: 400

Author(s)

Wen Han 1, Tian Li 2

Affiliation(s)

1 Guangxi Taibang Health Technology Co, Ltd, Nanning, Guangxi, China
2 Guangxi Gengyang Health Technology Co, Ltd, Yulin, Guangxi, China

Corresponding Author

Wen Han

ABSTRACT

This study mainly focused on the supply and use of drugs in the Mongolian Autonomous Prefecture of Xinjiang Uygur Autonomous Region, investigated the actual supply and use of drugs purchased in public hospitals of the autonomous region in China, compared the sales volume of national drugs and the total sales volume of related drugs after the implementation of the national centralized procurement policy. The objective is to understand the coverage and practical application of the drug supply scope of major medical reform policies in the autonomous region, as well as the key factors affecting the utilization rate of national centralized drug procurement in the autonomous region. It is clear whether the coverage rate of drugs for major diseases in the centralized drug procurement scope organized by the state is more conducive to reducing the burden on the people.

KEYWORDS

Medical reform; drug supply; influencing factors; voriconazole tablets; isosorbide mononitrate sustained-release tablets

CITE THIS PAPER

Wen Han, Tian Li, Study on the Influence of National Centralized Drug Procurement on Drug Use in Hospitals in Border Areas—Take Bayingolin Mongolian Autonomous Region of Xinjiang Autonomous Region as an Example. MEDS Public Health and Preventive Medicine (2023) Vol. 3: 11-18. DOI: http://dx.doi.org/10.23977/phpm.2023.030302.

REFERENCES

[1] Mao W, Vu H, Xie Z, et al. Systematic review on irrational use of medicines in China and Vietnam. PLoS One 2015; 10: e0117710. 
[2] Mao W, Chen W. The zero Mark-up policy for essential medicines at primary level facilities. Background paper, China. 2015. 
[3] Kang S Y, DiStefano M J, Socal M P, et al. Using external reference pricing in Medicare Part D to reduce drug price differentials with other countries. Health Affairs, 2019, 38(5): 804-811. 
[4] Joint Procurement Office. Announcement of the results of the planned selection of centralized drug procurement in 4 + 7 cities. 2018. 
[5] Wang J, Yang Y, Xu L, Shen Y, Wen X, Mao L et al. The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database. medRxiv 2021. 06. 21. 21256568. 2021. 
[6] National Academies of Sciences EAM, Division HAM, Services BOHC, Therapies COEP. Making Medicines Affordable: A National Imperative. Washington (DC): National Academies Press (US); 2017. 
[7] Yang Y., Tong R., Yin S. et al. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis. BMC Health Serv Res 21, 1275 (2021). 
[8] Lu J, Long H, Shen Y, Wang J, Geng X, Yang Y, Mao Z, Li J. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China. Front Pharmacol. 2022 Aug 23; 13: 923209. 
[9] Long H, Yang Y, Geng X, Mao Z, Mao Z. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series. Front Pharmacol. 2022 Jul 15; 13:944540. 
[10] Huang A, Wang X, Tao Y, Lin L, Cheng H. Healthcare professionals' knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: A cross-sectional study. Front Pharmacol. 2022 Oct 7; 13: 996824.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1922
Visits: 86377

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.